Le Lézard
Classified in: Health, Science and technology
Subjects: Trade Show, Survey

Immune-Onc Therapeutics to Present Data Supporting Therapeutic Potential of LAIR1 Antagonist Antibodies at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting


Immune-Onc Therapeutics, Inc. ("Immune-Onc"), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced that the Company will present a scientific poster at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021) being held November 10-14, 2021, in Washington, D.C., USA.

The poster will feature key preclinical data demonstrating the therapeutic potential of anti-LAIR1 antagonistic antibodies as immune checkpoint inhibitor therapy for solid tumors. LAIR1 (Leukocyte Associated Immunoglobulin-like Receptor 1) is an immune inhibitory transmembrane glycoprotein expressed on lymphocytes and myeloid cells and is activated by collagen and other ligands. Collagen is highly abundant in the stroma of many solid tumor types and thought to contribute to immune suppression. The data being presented suggest that LAIR1 blockade could potentially reverse collagen-mediated myeloid cell tolerogenic phenotype and T-cell suppression, thereby promoting a pro-inflammatory solid tumor microenvironment.

Presentation Details

Poster Title:

Antagonistic Antibodies Targeting LAIR1 Enhance T Lymphocyte Activation and Promote Inflammatory Phenotypes in Myeloid Cells

Abstract ID:

304

Presenter:

Tao Huang, PhD, Director of Preclinical Development at Immune-Onc Therapeutics

Category:

Checkpoint Blockade Therapy

Date:

Saturday, Nov. 13, 2021

Time:

7:00 am ? 8:30 pm EST

Location:

Poster Hall at the Walter E. Washington Convention Center, D.C.

Poster presentations will be accessible in person and virtually. The poster will also be made available on the "Publications & Abstracts" section of the Company's website.

ABOUT IMMUNE-ONC THERAPEUTICS, INC.

Immune-Onc Therapeutics, Inc. ("Immune-Onc") is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment.

Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. Immune-Onc's focused platform approach has led to the development of several promising therapeutics across various stages of development, including IO-108 in Phase 1 clinical development for solid tumors and IO-202, a first-in-class antibody targeting LILRB4 (also known as ILT3), in Phase 1 clinical development for the treatment of acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). The company also plans to evaluate IO-202 in solid tumors in 1H2022. The U.S. Food and Drug Administration granted IO-202 Orphan Drug Designation for treatment of AML in October 2020. Additional assets in Immune-Onc's pipeline include IO-106, a first-in-class anti-LAIR1 antibody, and multiple undisclosed programs for solid tumors and hematologic malignancies.

The company has strategic research collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center, and has invested in proprietary models, assays, and tools to interrogate the biology and translate this cutting-edge research into the development of novel therapies. Immune-Onc has received research grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) and a strategic investment from The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP®). Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit www.immune-onc.com and follow us on Twitter and LinkedIn.


These press releases may also interest you

at 13:55
An expert panel has published the first performance measures to identify remission and evaluate the effectiveness of lifestyle medicine treatments, which will allow more objective comparisons between lifestyle behavior interventions and other...

at 13:51
BRIJ Medical proudly welcomes three distinguished industry leaders to its Board of Directors: John Grotting, Bob Zollars, and Jim Hinrichs. Leveraging their extensive experience and insights, they will steer the company's strategic vision and drive...

at 13:47
Everyone deserves to succeed. But today, for too many Canadians, your hard work isn't paying off like it did for previous generations. Your paycheque doesn't go as far as costs go up, and saving enough to go after your dreams seems harder and harder....

at 13:41
With sadness, AAD announced today that its influential board member and investor James Herbert has died following a lengthy battle with cancer. He was 83....

at 13:40
March is Women's History Month, and for the first time in U.S. history, four women legislators are leading the four organizations that make up the Quad Caucus, a collaborative initiative comprised of the National Caucus of Native American Caucus of...

at 13:24
Susan G. Komen®, the world's leading breast cancer organization, applauds Representative Patty Acomb (D-Minnetonka) for introducing legislation that would eliminate financial barriers to clinically appropriate genetic testing, as well as the...



News published on and distributed by: